Yi Liu

Yi Liu

Auto-generated profile, based on publicly available information

Yi Liu

Humanities School, Beijing University of Chinese Medicine, Beijing, 100029, People’s Republic of China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
GCguangyao chen
guangyao chen
JLJing Luo
Jing Luo
YLYi Liu
Yi Liu
XYXin-Bo Yu
Xin-Bo Yu
XLXiao-Yu Liu
Xiao-Yu Liu
QTQingwen Tao
Qingwen Tao
Objective: The study aimed to explore the mechanism of total flavonoids of Rhizoma Drynariae (TFRD) in the treatment of rheumatoid arthritis (RA) based on network pharmacology and experimental validation. Methods: The active components of TFRD were identified from TCMSP and TCMID databases. Relevant targets of the active compounds of TFRD and RA-related targets were predicted by public databases online. A component-target (C-T) regulatory network was constructed by Cytoscape. The genes of TFRD regulating RA were imported into STRING database to construct a protein-protein interaction (PPI) network in order to predict the key targets. KEGG enrichment analysis was performed to predict the crucial mechanism of TFRD against RA. The active components of TFRD underwent molecular docking with the key proteins. Collagen-induced arthritis (CIA) model of rats and inflammatory factors-stimulated fibroblast-like synoviocytes were used in vivo and in vitro to validate the efficacy and predicted critical mechanisms of TFRD. Results: Network Pharmacology analysis revealed that TFRD had 14 active compounds, corresponding to 213 targets, and RA related to 2814 genes. There were 137 intersection genes between TFRD and RA. KEGG indicated that therapeutic effects of TFRD on RA involves T cell receptor signaling pathway, Th17 cell differentiation, IL-17 signaling pathway, TNF signaling pathway, MAPK signaling pathway and PI3K/AKT signaling pathway. In vivo experiments suggested TFRD can alleviate the inflammatory response, joint swelling and synovial abnormality of CIA rats. TFRD contributed to the decrease of Th17 cells and the down-regulated secretion of IL-17A and TNF-α of activated lymphocyte in CIA model. In vitro experiments confirmed TFRD can effectively inhibit the inflammatory response of fibroblast-like synoviocytes and suppress the abnormal activation of MAPK, PI3K/AKT and NFκB signaling pathways. Conclusion: The treatment of RA with TFRD is closely related to inhibiting Th17 differentiation and inflammatory response of synoviocytes.

27 September 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
QJQi Jin
Qi Jin
JLJie Li
Jie Li
GCguangyao chen
guangyao chen
ZWZi-Yu Wu
Zi-Yu Wu
XLXiao-Yu Liu
Xiao-Yu Liu
YSYuehan Song
Yuehan Song
Objective: The mechanism of Wendan Decoction (WDD) against Generalized Anxiety Disorder (GAD) was predicted by network pharmacology and validated by in vivo and in vitro experiments. Methods: The targets of WDD for the treatment of GAD were obtained by a search of online databases. Further, PPI network and KEGG enrichment were used to identify the key targets and pathways. Ultimately, these key targets and pathways were validated by in vivo experiments on GAD mice modeled by repeated restraint stress (RRS) and in vitro experiments on inflammatory factor stimulated BV-2 cells. Results: Through searching the databases, the 137 ingredients of WDD that correspond to 938 targets and 4794 targets related to GAD were identified. Among them, 569 overlapping targets were considered as the therapeutic targets of WDD for GAD. PPI analysis showed that the inflammation-related proteins IL-6, TNF, SRC and AKT1 were the key targets, and KEGG enrichment suggested that PI3K/AKT and MAPK signaling pathways were key pathways of WDD in the treatment of GAD. In vivo experiments, RRS mice exhibited abnormality in behavioristics in open field test (OFT) and elevated plus maze (EPM) and increases in serum corticosterone and the percentage of lymphocytes positive for IL-6 in peripheral blood. These abnormal changes can be reversed by WDD and the positive control drug paroxetine. In vitro experiments, WDD can inhibit IL-6 induced activation of PI3K/AKT and MAPK signaling pathways in BV2 cells, and suppress the ensuing release of inflammatory factors TNF-α, IL-1β and PGE2, and showed a dose-dependent effect. Conclusion: WDD is able to resist GAD by relieving inflammatory response in peripheral and central system.

8 June 2022 in Computational and Mathematical Methods in Medicine
Verified
Journal Article
Open access
PDF file
GCguangyao chen
guangyao chen
XLXiao-Yu Liu
Xiao-Yu Liu
JLJing Luo
Jing Luo
XYXin-Bo Yu
Xin-Bo Yu
YLYi Liu
Yi Liu
QTQingwen Tao
Qingwen Tao
Background. Gubitong Recipe (GBT) is a prescription based on the Traditional Chinese Medicine (TCM) theory of tonifying the kidney yang and strengthening the bone. A previous multicentral randomized clinical trial has shown that GBT can effectively relieve joint pain and improve quality of life with a high safety in treating osteoarthritis (OA). This study is aimed at elucidating the active compounds, potential targets, and mechanisms of GBT for treating OA. Method. The network pharmacology method was used to predict the key active compounds, targets, and mechanisms of GBT in treating OA. An OA rat model was established with Hulth surgery, and the pathological changes of articular cartilage were observed to evaluate the effects of GBT. Chondrocytes were stimulated with LPS to establish in vitro models, and key targets and mechanisms predicted by network pharmacology were verified via qRT-PCR, ELISA, western blot, and immunofluorescence. The Contribution Index Model and molecular docking were used to determine the key active compounds of GBT and the major nodes affecting predicted pathways. Result. A total of 500 compounds were acquired from related databases, where 87 active compounds and their 254 corresponding targets were identified. 2979 OA-related genes were collected from three databases, 150 of which were GBT-regulating OA genes. The compound-target network weight analysis and PPI results showed that IL-6 and PGE2 are key targets of GBT in treating OA. KEGG results showed that PI3K/AKT, Toll-like receptor, NFκB, TNF, and HIF-1 are the key signaling pathways. An in vivo experiment showed that GBT could effectively suppress cartilage degradation of OA rats. In vitro experiments demonstrated that GBT can inhibit the key targets of KEGG-related pathways. Molecular-docking results suggested that luteolin, licochalcone A, and β-carotene were key targets of GBT, and the mechanisms may be associated with the NFκB signaling pathway. Blockage experiments showed that the NFκB pathway is the key pathway of GBT in treating OA. Conclusion. This study verified that GBT can effectively protect articular cartilage through multitarget and multipathway, and its inhibitory effect on the NFκB pathway is the most key mechanism in treating OA.

1 August 2026 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
YWYifei Wang
Yifei Wang
YHYuxin Han
Yuxin Han
FTFei Teng
Fei Teng
YLYi Liu
Yi Liu
LMLiangjie Ma
Liangjie Ma
XMXiao Ma
Xiao Ma
Objective: The total glucosides of paeony (TGP), extracted from the roots of Paeonia lactiflora Pall., represent its primary bioactive fraction. Emerging evidence supports its clinical potential in treating ulcerative colitis (UC). Nevertheless, a systematic understanding of its underlying pharmacological mechanisms remains insufficient. This study aims to comprehensively investigate the multi-target, multi-pathway therapeutic mechanisms of TGP against UC by employing an integrated strategy combining network pharmacology and untargeted metabolomics, with subsequent experimental validation. Methods: Induction of the colitis mouse model was performed by supplementing drinking water with dextran sulfate sodium (DSS), and an in vitro model was created by treating NCM460 intestinal epithelial cells with lipopolysaccharide. The DSS-induced colitis mice were orally administered low-, medium-, or high-dose TGP at 0.093, 0.185, or 0.369 g/kg/day, respectively, while LPS-stimulated NCM460 cells were treated with TGP at 100, 200, or 400 μg/mL. The therapeutic effects of TGP were assessed in vivo through the disease activity index (DAI), colon length measurement, and histopathological examination. Colon tissues were collected for subsequent non-targeted metabolomics analysis via liquid chromatography- tandem mass spectrometry (LC-MS/MS). The mechanisms underlying the effects of TGP were explored through integrated network pharmacology and metabolomics studies and further verified using RT-PCR, ELISA, Western blot, and flow cytometry. Results: TGP treatment significantly decreased DAI scores, reduced colon shortening, and ameliorated histopathological lesions in the DSS-induced colitis mouse model. Network pharmacology analysis revealed that the therapeutic effects of TGP on UC are primarily mediated through various inflammatory mediators and signaling pathways. Integrated metabolomics analysis further identified the COX-2-mediated arachidonic acid pathway as a key pathway. Both in vivo and in vitro, TGP dose-dependently reduced the expression of IL-6, TNF-α, and COX-2 and suppressed the activation of AKT, p38 MAPK, and NF-κB signaling. In DSS-treated mice, TGP-H reduced the splenic Th17/Treg ratio. Conclusion: TGP exerts its therapeutic effects on UC through the inhibition of various inflammatory targets and signaling pathways.